FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma

FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma

Background: Most patients with advanced pancreatic adenocarcinoma (PA) treated with FOLFIRINOX experience adverse events requiring dose reduction. We aimed to assess the association between relative dose intensity (RDI) and disease control in a European setting. Methods: We retrospectively included...

Full description

Bibliographic Details
Main Authors: Antonin Vary, Loïc Lebellec, Frédéric Di Fiore, Nicolas Penel, Claire Cheymol, Emilia Rad, Farid El Hajbi, Astrid Lièvre, Julien Edeline, André Michel Bimbai, Marie-Cécile Le Deley, Anthony Turpin
Format: Article
Language:English
Published: SAGE Publishing 2021-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359211029825

Internet

https://doi.org/10.1177/17588359211029825

Similar Items